145 related articles for article (PubMed ID: 2541937)
1. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
Carmichael J; Cantwell BM; Edwards CM; Zussman BD; Thompson S; Rapeport WG; Harris AL
Cancer Chemother Pharmacol; 1989; 24(1):45-9. PubMed ID: 2541937
[TBL] [Abstract][Full Text] [Related]
2. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Addelman M; Erlichman C; Fine S; Warr D; Murray C
J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
5. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
[TBL] [Abstract][Full Text] [Related]
7. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
Plosker GL; Goa KL
Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376
[TBL] [Abstract][Full Text] [Related]
8. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group.
Joss RA; Dott CS
Eur J Cancer; 1993; 29A Suppl 1():S22-9. PubMed ID: 8381293
[TBL] [Abstract][Full Text] [Related]
9. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766
[TBL] [Abstract][Full Text] [Related]
10. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
11. Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group.
Kamanabrou D
Eur J Cancer; 1992; 28A Suppl 1():S6-11. PubMed ID: 1320919
[TBL] [Abstract][Full Text] [Related]
12. The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group.
Chevallier B
Br J Cancer; 1993 Jul; 68(1):176-80. PubMed ID: 8391304
[TBL] [Abstract][Full Text] [Related]
13. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease.
Carmichael J; Philip PA; Forfar C; Harris AL
Cancer Chemother Pharmacol; 1995; 37(1-2):134-8. PubMed ID: 7497582
[TBL] [Abstract][Full Text] [Related]
14. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
Bermudez J; Boyle EA; Miner WD; Sanger GJ
Br J Cancer; 1988 Nov; 58(5):644-50. PubMed ID: 2851311
[TBL] [Abstract][Full Text] [Related]
15. Repeated use of granisetron in patients receiving cytostatic agents.
de Wet M; Falkson G; Rapoport BL
Cancer; 1993 Jun; 71(12):4043-9. PubMed ID: 8389659
[TBL] [Abstract][Full Text] [Related]
16. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
Soukop M
Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
[TBL] [Abstract][Full Text] [Related]
17. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
Marty M
Eur J Cancer; 1992; 28A Suppl 1():S12-6. PubMed ID: 1320913
[TBL] [Abstract][Full Text] [Related]
18. Dose granisetron remain effective over multiple cycles? The Granisetron Study Group.
Blijham GH
Eur J Cancer; 1992; 28A Suppl 1():S17-21. PubMed ID: 1320914
[TBL] [Abstract][Full Text] [Related]
19. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.
Cassidy J; Raina V; Lewis C; Adams L; Soukop M; Rapeport WG; Zussman BD; Rankin EM; Kaye SB
Br J Cancer; 1988 Nov; 58(5):651-3. PubMed ID: 2851312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
